|
Abstract:
|
In oncology clinical trials, overall survival remains the regulatory gold standard. However, patient populations with relatively long median such as 3 years survival will slow the trial completion. Therefore surrogate endpoints such as PFS or PSA progression with early result are desired, and their correlation with overall survival need to be established in order to support for the approval base. In this research work, correlation between PFS, PSA progression and other endpoints with overall survival are evaluated using Spearman's correlation and Kendall's tau coefficients, which were estimated through various copula. Real data from multiple prostate cancer studies across different population or disease stages are applied. This exploratory work may assist the future endpoint analysis for prostate cancer studies.
|
